OVARIAN CARCINOMA
Clinical trials for OVARIAN CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN CARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise against Hard-to-Treat cancers
Disease control TerminatedThis early-phase study tested a new daily pill, NKT3447, in 23 adults with advanced solid tumors (like ovarian, endometrial, or lung cancer) that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was stopped early, so r…
Matched conditions: OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 01:01 UTC
-
Engineered immune cells take aim at hard-to-treat cancers
Disease control TerminatedThis study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique markers on their cancer cells. It involved 8 people with advanced solid tumors like lung, pancreatic, or ovarian cancer that had stopped responding …
Matched conditions: OVARIAN CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Alaunos Therapeutics • Aim: Disease control
Last updated May 17, 2026 00:53 UTC
-
Pfizer's new cancer drug trial halted early after testing in just 10 patients
Disease control TerminatedThis early-stage study tested a new drug called PF-07826390, given alone or with another drug (sasanlimab), in people with advanced solid tumors like lung, colon, kidney, and ovarian cancers. The goal was to check safety, find the right dose, and see if the drug shrinks tumors. O…
Matched conditions: OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
Ovarian cancer drug combo trial halted early
Disease control TerminatedThis early-stage trial tested a new drug (STRO-002) combined with bevacizumab in 58 people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The main goals were to check safety and find the best dose. The study was terminated, so results are limited.
Matched conditions: OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
Pfizer cancer drug trial halted early after only 9 patients
Disease control TerminatedThis early-stage study tested a new experimental drug (PF-07820435) alone or with another drug (sasanlimab) in people with advanced solid tumors like lung, skin, and kidney cancers. The goal was to check safety and find the right dose. Only 9 people took part before the study was…
Matched conditions: OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC